DemeRx IB, Inc., an atai Life Sciences platform company focused on developing ibogaine for the treatment of opioid use disorder, today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency to commence subject enrolment in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002).
atai Life Sciences’ DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company…
JOIN THE ATAI #INSIGHTNETWORK